样式: 排序: IF: - GO 导出 标记为已读
-
A Comprehensive Overview on Chemotherapy-Induced Cardiotoxicity: Insights into the Underlying Inflammatory and Oxidative Mechanisms Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-03-16 András Nagy, Denise Börzsei, Alexandra Hoffmann, Szilvia Török, Médea Veszelka, Nikoletta Almási, Csaba Varga, Renáta Szabó
-
Surgical Treatment for Type A Aortic Dissection after Endovascular Aortic Repair: A 12-year, Single-Center Study Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-03-15 Yuan Xue, Shipan Wang, Xuehuan Zhang, Xiaomeng Wang, Yue Shi, Hongjia Zhang, Duanduan Chen, Haiyang Li
-
Effectiveness of Vasopressin Against Cardiac Arrest: A Systematic Review of Systematic Reviews Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-03-12 Jonathan Ka-Ming Ho, Hon-Lon Tam, Leona Yuen-Ling Leung
-
The Impacts of Nirmatrelvir–Ritonavir on Myocardial Injury and Long-Term Cardiovascular Outcomes in Hospitalized Patients with COVID-19 amid the Omicron Wave of the Pandemic Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-03-11 Jun Gu, Zhi-Hua Han, Chang-qian Wang, Jun-feng Zhang
-
-
Exercise Improves Heart Function after Myocardial Infarction: The Merits of AMPK Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-03-04 Xiaodi Zhang, Yi Zhao, Dafen Guo, Mingxian Luo, Qing Zhang, Li Zhang, Dengshen Zhang
-
Aloperine Alleviates Myocardial Injury Induced by Myocardial Ischemia and Reperfusion by Activating the ERK1/2/β-catenin Signaling Pathway Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-02-28 Shichao Wei, Feng Ju, Junshen Xiao, Jiaxue Li, Ting Liu, Zhaoyang Hu
-
An Integrated Network Pharmacology and RNA-seq Approach for Exploring the Protective Effect of Andrographolide in Doxorubicin-Induced Cardiotoxicity Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-02-24 Sa Liu, Jiaqin Liu, Nan Su, Shanshan Wei, Ning Xie, Xiangyun Li, Suifen Xie, Jian Liu, Bikui Zhang, Wenqun Li, Shengyu Tan
-
A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-02-16 Hani Sabbour, Deepak L. Bhatt, Yaser Elhenawi, Asma Aljaberi, Layal Bennani, Tarek Fiad, Khwaja Hasan, Shahrukh Hashmani, Rabih A. Hijazi, Zafar Khan, Ronney Shantouf
-
Isoimperatorin Inhibits Angiogenesis by Suppressing VEGFR2 Signaling Pathway Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-02-16 Yating Xu, Di Xia, Shan Deng, Minglu Liang
-
Safety and Effectiveness of Antidysrhythmic Drugs for Pharmacologic Cardioversion of Recent-Onset Atrial Fibrillation: a Systematic Review and Bayesian Network Meta-analysis Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-02-07 Ian S. deSouza, Pragati Shrestha, Robert Allen, Jessica Koos, Henry Thode
-
Dapagliflozin for Atrial Fibrillation Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-02-06 Na Li, Mihail G. Chelu, Yochai Birnbaum
-
Acute Kidney Injury in Different Anticoagulation Strategies: A Large-Scale Pharmacoepidemiologic Study Using Real-World Data Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-02-06
Abstract Purpose Acute kidney injury (AKI) following anticoagulant application has received growing attention as a significant emerging complication of anticoagulation. Nevertheless, there remains a lack of real-world studies to compare the incidence, clinical features, and prognosis of AKI across different anticoagulant regimens. Methods Disproportionality analysis and Bayesian analysis were used
-
Changes in Heart Rate Variability Parameters Following Radiofrequency Ablation in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-01-30 Mahsa Mansourian, Zahra Teimouri-jervekani, Azam Soleimani, Rasool Nouri, Hamidreza Marateb, Marjan Mansourian
-
Hyperkalaemia in Cardiological Patients: New Solutions for an Old Problem Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-01-30 Maurizio Giuseppe Abrignani, Edoardo Gronda, Marco Marini, Mauro Gori, Massimo Iacoviello, Pier Luigi Temporelli, Manuela Benvenuto, Giulio Binaghi, Arturo Cesaro, Alessandro Maloberti, Maria Denitza Tinti, Carmine Riccio, Furio Colivicchi, Massimo Grimaldi, Domenico Gabrielli, Fabrizio Oliva
-
The Function of Circular RNAs in Myocardial Ischemia–Reperfusion Injury: Underlying Mechanisms and Therapeutic Advancement Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-01-30 Kai-Yuan Chen, Zhou Liu, Jun-Hou Lu, Si-Yuan Yang, Xuan-Yi Hu, Gui-You Liang
-
The Toll-like Receptor-2/4 Antagonist, Sparstolonin B, and Inflammatory Diseases: A Literature Mining and Network Analysis Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-01-25
Abstract Background Sparstolonin B (SsnB) is characterized as a new toll-like receptor (TLR)-2/4 antagonist. However, the effects of SsnB on different inflammatory diseases have not been systemically reviewed. Methods We investigated the effects of SsnB on inflammatory diseases with data mining and network analysis of literature, including frequency description, cluster analysis, association rule mining
-
Comparison Between Drug-Coated Balloon and Stents in Large De Novo Coronary Artery Disease: A Systematic Review and Meta-Analysis of RCT Data Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-01-25 Zhiqiang Ma, Kanling Liu, Yanhui Hu, Xiwen Hu, Binyu Wang, Zhengyi Li
-
Metabolism Serves as a Bridge Between Cardiomyocytes and Immune Cells in Cardiovascular Diseases Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-01-18 Lixiao Hang, Ying Zhang, Zheng Zhang, Haiqiang Jiang, Lin Xia
-
Evaluation of Midodrine Utilization in Patients with Cancer and Heart Failure Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-01-15 Jorge A. Irizarry-Caro, Juhee Song, Chase Miller, Shyam Desai, James Going, Jose Fossas-Espinosa, Mariya M. Fatakdawala, Abdelrahman Ali, Cezar Iliescu, Nicolas Palaskas, Anita Deswal, Efstratios Koutroumpakis
-
The Impact of CYP2C19 Genotype on the Platelet Reactivity Index (PRI) among Chronic Coronary Syndromes (CCS) Patients Undergoing Percutaneous Coronary Intervention (PCI): Affectability of Rapid Genetic Testing Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-01-15 Mohammed Ahmed Akkaif, Nur Aizati Athirah Daud, Dzul Azri Mohamed Noor, Abubakar Sha’aban, Muhamad Ali SK Abdul Kader, Baharudin Ibrahim
-
Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-01-12
Abstract Purpose Reduction of major atherosclerotic cardiovascular events (MACE) has not been consistent among different glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes mellitus (T2DM). The aim of this study was to assess the association between the magnitude of glycemic control, body weight loss, and reductions in systolic blood pressure (SBP) and low-density
-
Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Low Body Weight Patients with Atrial Fibrillation: A Systematic Review and Meta-analysis Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2024-01-02 Mohamed Nabil Elshafei, Muhammad Salem, Ahmed El-Bardissy, Mohamed S. Abdelmoneim, Ahmed Khalil, Sherine Elhadad, Mutasem Al Mistarihi, Mohammed Danjuma
-
MOTS-c Peptide Attenuated Diabetic Cardiomyopathy in STZ-Induced Type 1 Diabetic Mouse Model Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-12-23
Abstract Background Diabetic cardiomyopathy (DCM) pathogenesis is a common complication of diabetes, but effective treatments remain limited. Mitochondrial-derived peptide MOTS-c has shown therapeutic promise in animal models of various heart diseases, but its efficacy in DCM is unknown. This study investigates the effects of MOTS-c treatment in a mouse model of type 1 diabetes-induced DCM. Methods
-
The Infarct-Limiting Effect of Remote Ischemic Conditioning in Rats Is Not Affected by Aspirin Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-12-20 M. V. Basalay, James M. Downey, S. M. Davidson, D. M. Yellon
-
Interplay Between TGF-β Signaling and MicroRNA in Diabetic Cardiomyopathy Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-12-20 Jianning Qin, Yao Tan, Yang Han, Letian Yu, Shali Liu, Simin Zhao, Hengquan Wan, Shunlin Qu
-
Influence of a Short Course of Ritonavir Used as Booster in Antiviral Therapies Against SARS-CoV-2 on the Exposure of Atorvastatin and Rosuvastatin Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-12-19 Evelyn Krohmer, Brit Silja Rohr, Felicitas Stoll, Katja S. Gümüs, Mariano Bergamino, Gerd Mikus, Max Sauter, Jürgen Burhenne, Johanna Weiss, Andreas D. Meid, David Czock, Antje Blank, Walter E. Haefeli
-
ROS-Activated TRPM2 Channel: Calcium Homeostasis in Cardiovascular/renal System and Speculation in Cardiorenal Syndrome Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-12-18 Zihan Chen, Zaihua Cheng, Congcong Ding, Tianyu Cao, Ling Chen, Hong Wang, Junpei Li, Xiao Huang
-
Oral Anticoagulation for Atrial Fibrillation in Octogenarians Across the Renal Function Spectrum Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-12-18 Andreina Carbone, Roberta Bottino, Emilio Attena, Valentina Parisi, Maddalena Conte, Antonello D’Andrea, Egidio Imbalzano, Caturano Alfredo, Vincenzo Russo
-
Establishment and Validation of the Nomogram Model and the Probability of Silent Cerebral Infarction After Ablation Atrial Fibrillation Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-12-16 Wei Bao, Xiaoqin Hu, Liqi Ge, Shiyun Tang, Xinliang Zhao, Shuo Huang, Chen Liu, Fei Li, Chaoqun Zhang, Chengzong Li
-
Colchicine Attenuates Microvascular Obstruction after Myocardial Ischemia-Reperfusion Injury by Inhibiting the Proliferation of Neutrophil in Bone Marrow Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-12-08 Ying Tan, Xue Bao, Yuyu Li, Guo Song, He Lu, Xuan Sun, Rong Gu, Lina Kang, Biao Xu
-
Beyond Hepatoprotection—The Cardioprotective Effects of Bicyclol in Diabetes Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-12-06 Arun Samidurai, Rakesh C. Kukreja
-
Impact of CYP2C19 Genotype on Efficacy and Safety of Clopidogrel-based Antiplatelet Therapy in Stroke or Transient Ischemic Attack Patients: An Updated Systematic Review and Meta-analysis of Non-East Asian Studies Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-12-01 Sarah Cargnin, Federica Ferrari, Salvatore Terrazzino
-
-
Comparison of Efficacy and Safety Between Drug-Coated Balloons Versus Drug-Eluting Stents in the Treatment of De Novo Coronary Lesions in Large Vessels: A Study-Level Meta-Analysis of Randomized Control Trials Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-11-24 Bing Sun, Xu Tong Zhang, Rui Rui Chen
-
Nicotinamide Riboside Supplementation Restores Myocardial Nicotinamide Adenine Dinucleotide Levels, Improves Survival, and Promotes Protective Environment Post Myocardial Infarction Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-11-24 Cynthia Tannous, Rana Ghali, Ahmed Karoui, Nada J. Habeichi, Ghadir Amin, George W. Booz, Mathias Mericskay, Marwan Refaat, Fouad A. Zouein
-
Intervention of Tanshinone IIA on the PGK1-PDHK1 Pathway to Reprogram Macrophage Phenotype After Myocardial Infarction Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-11-22 Shan Gao, Zhihui Yang, Dan Li, Bingkai Wang, Xu Zheng, Chong Li, Guanwei Fan
-
Agathis dammara Extract and its Monomer Araucarone Attenuate Abdominal Aortic Aneurysm in Mice Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-11-18 Qingyi Zhang, Zeyu Cai, Zhewei Yu, Chang Di, Yingkun Qiu, Rong Qi
-
Possible Cardioprotective Effects of Lactate Infusion After Cardiac Arrest or Prolonged Myocardial Ischemia Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-11-14 Takashi Koyama
-
IL-33 Suppresses the Progression of Atherosclerosis via the ERK1/2-IRF1-VCAM-1 Pathway Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-11-14 Zhang Qian, Feng Shaofang, Chen Chen, Shi Chunhua, Wang Nan, Liu Chao
-
Hyperoside Protects Trastuzumab-Induced Cardiotoxicity via Activating the PI3K/Akt Signaling Pathway Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-11-09 Shanshan Wei, Wanjun Ma, Suifen Xie, Sa Liu, Ning Xie, Wenqun Li, Bikui Zhang, Jian Liu
-
Therapeutic Approaches Targeting Ferroptosis in Cardiomyopathy Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-11-06 Yanqian Ruan, Ling Zhang, Lina Zhang, Keyang Zhu
-
Pharmacodynamic Drug-Drug Interactions and Bleeding Outcomes in Patients with Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants: a Nationwide Cohort Study Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-11-06 Maxim Grymonprez, Andreas Capiau, Stephane Steurbaut, Koen Boussery, Els Mehuys, Annemie Somers, Mirko Petrovic, Tine L. De Backer, Lies Lahousse
-
Contemporary Medical Management of Peripheral Arterial Disease Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-11-02 Ian O. Cook, Jayer Chung
-
Effects of Dapagliflozin on Myocardial Gene Expression in BTBR Mice with Type 2 Diabetes Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-11-02 Maria Ryaboshapkina, Regina Ye, Yumei Ye, Yochai Birnbaum
-
The Role of Macrophages in Atherosclerosis: Participants and Therapists Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-10-21 Xiaoyu Liu, Shuchao Pang, Yangyang Jiang, Lixin Wang, Yi Liu
-
Winding Down the Storm: Could Empagliflozin’s Ion-Dependent Mechanisms Tackle the Ventricular Arrhythmia Burden in Chronic Chagas Cardiomyopathy? Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-10-16 Sergio Alejandro Gómez-Ochoa, Lyda Z. Rojas, Luis Eduardo Echeverría
-
Early Initiation of SGLT2 Inhibitors in Acute Heart Failure: a Focus on Diuresis and Renal Protection Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-10-13 Andreas Hammer, Alexander Niessner, Patrick Sulzgruber
Purpose Acute heart failure (AHF) represents a critical and life-threatening condition characterized by the sudden onset or exacerbation of symptoms, such as dyspnea and fluid retention, due to impaired cardiac function. Despite advances in the treatment of chronic heart failure (HF), the management of AHF remains challenging, with limited therapeutic options available. Sodium-glucose cotransporter
-
The Effects of Sacubitril/Valsartan Compared to Olmesartan on the Blood Pressure and Glucolipid Metabolism in DM Patients with Primary Hypertension Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-10-13 Shuang Zhang, Zheng Yin, Zhi-Fan Li, Wen-Jia Zhang, Yong-Gang Sui, Yan-Lu Xu, Hai-Tao Zhang, Xiao-Ning Liu, Hong Qiu, Jing-Lin Zhao, Jian-Jun Li, Ke-Fei Dou, Jie Qian, Na-Qiong Wu
-
Effect of Intensive Lipid-Lowering Therapy on Coronary Plaque Stabilization Derived from Optical Coherence Tomography: a Meta-analysis and Meta-regression Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-10-10 Sen Liu, Jixin Hou, Jindong Wan, Yi Yang, Dan Wang, Dengpan Liang, Xinquan Wang, Peng Zhou, Peijian Wang
-
Minimal Adherence Threshold to Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation to Reduce the Risk of Thromboembolism and Death: A Nationwide Cohort Study Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-09-14 Maxim Grymonprez, Stephane Steurbaut, Andreas Capiau, Delphine Vauterin, Frauke Van Vaerenbergh, Els Mehuys, Koen Boussery, Tine L. De Backer, Lies Lahousse
-
Long Non-coding RNA Involved in the Pathophysiology of Atrial Fibrillation Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-09-13 Zikan Zhong, Xintao Li, Longzhe Gao, Xiaoyu Wu, Yutong Ye, Xiaoyu Zhang, Qingye Zeng, Changzuan Zhou, Xiaofeng Lu, Yong Wei, Yu Ding, Songwen Chen, Genqing Zhou, Juan Xu, Shaowen Liu
-
Trimetazidine to Reduce Myocardial Fibrosis-Competing Interests with SGLT2 Inhibitors? Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-09-13 Tyler B Moran,Masafumi Kitakaze,Yochai Birnbaum
-
Evaluation of the Efficacy of Sacubitril/Valsartan on Radiofrequency Ablation in Patients with Hypertension and Persistent Atrial Fibrillation Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-09-07 Xiaobiao Zang, Zhihan Zhao, Ke Chen, Weifeng Song, Jifang Ma, You Zhou, Erpeng Liang, Haixia Fu, Xianqing Wang, Yonghui Zhao, Rongfeng Zhang
-
A Novel Parallel Wire-based Antegrade Dissection Re-entry Technique for Failed Retrograde Attempt of Coronary Chronic Total Occlusions with Risk Nomogram Analysis Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-09-07 Yuanji Ma, Hao Lu, Yiqing Hu, Jianquan Liao, Jianying Ma, Chenguang Li, Lei Ge, Juying Qian, Kang Yao, Junbo Ge
-
Effects of Rhythm Control for Atrial Fibrillation on Cardiac Remodeling and Valvular Regurgitation in Patients with Heart Failure Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-08-30 Jinping Si, Zijie Ding, Xuefu Chen, Lin Bai, Yuxi Sun, Xinxin Zhang, Yanli Zhang, Yunlong Xia, Ying Liu
-
Pulmonary Circulation Under Pressure: Pathophysiological and Therapeutic Implications of BK Channel Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-08-25 Thais S. Barenco-Marins, Fernando A. C. Seara, Cristiano G. Ponte, Jose H. M. Nascimento
-
Exercise Prevents Glucocorticoid-Induced Myocardial 4-Hydroxynonenal Production Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-08-25 Umit Hayta, Senay Akin, Irem Gungor, Inci Tugce Colluoglu, Umit Guray, Yesim Akin, Haydar A. Demirel
-
PDHA1 Alleviates Myocardial Ischemia-Reperfusion Injury by Improving Myocardial Insulin Resistance During Cardiopulmonary Bypass Surgery in Rats Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-08-23 Kai-Yuan Chen, Zhou Liu, Jing Yi, Yong-Peng Hui, Ying-Nan Song, Jun-Hou Lu, Hong-Jin Chen, Si-Yuan Yang, Xuan-Yi Hu, Deng-Shen Zhang, Gui-You Liang
-
Does Genotype Affect the Efficacy of PCSK9 Inhibitors in the Treatment of Familial Hypercholesterolemia? Cardiovasc. Drugs Ther. (IF 3.4) Pub Date : 2023-08-23 Fistra Janrio Tandirerung
Purpose of Review This review discusses whether patients’ genotype affects the efficacy of PCSK9 inhibitors in treating familial hypercholesterolemia and how this might influence clinical management. Recent Findings Currently, available evidence consistently demonstrates and is in good agreement that, in general, the LDL-C-lowering effect of PCSK9 inhibitors is similar across genotypes, except for